Pembrolizumab in Hepatocellular Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2018

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions

HCC

Interventions

DRUG

pembrolizumab

200mg every 3 weeks infusion

Trial Locations (1)

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong

All Listed Sponsors

lead

CCTU

OTHER

NCT03419481 - Pembrolizumab in Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter